Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide, especially in East Asia. ESCC accounts for more than 90% of esophageal cancer. Currently, neoadjuvant therapy in combination with surgical resection is the mainstay of treatment. However, the overall survival rate of patients with locally advanced ESCC is not satisfactory even when treated following the standard treatment guidelines. With neoadjuvant chemoradiotherapy, chemotherapy, or emerging immunotherapy, continuous exploration of efficacy in relation to ESCC is expected to improve overall survival further. Here, we review and summarize current evidence for efficacy of preoperative therapy for locally advanced ESCC.

Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma

“…Trials showed that neoadjuvant chemoradiotherapy improved the OS compared with all other treatment modalities, including neoadjuvant chemotherapy, neoadjuvant radiotherapy and surgery alone. However, the risk of postoperative mortality after neoadjuvant chemoradiotherapy also increased significantly compared with that of surgery alone or neoadjuvant chemotherapy + surgery (9). So patients who received neoadjuvant chemoradiotherapy are relatively less and are more likely to receive neoadjuvant chemotherapy.…”

Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery

“…2 The mortality and incidence rates of ESCC are currently higher in East Asian countries, especially in China. 3 Previously, surgery alone was the standard primary treatment modality for early ESCC, offering a 5-year survival rate of up to 80%. However, surgery alone yields poor outcomes, and the mortality rate is up to 5% for locally advanced ESCC.…”

Screening and Evaluating Novel Autoantibodies Based on Proteomic Chips in Diagnosis of Esophageal Squamous Cell Carcinoma

“…East Asia had the highest incidence of EC, and China had the heaviest burden [1]. The current clinical treatment of EC included surgery, targeted drug therapy, adjuvant radiotherapy and chemotherapy [22][23][24][25][26][27]. However, only relying on current medical technology, the ve-year survival rate was only between 15%-20% [3] .…”